Navigation Links
GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health
Date:11/24/2014

SAN DIEGO, Nov. 24, 2014 /PRNewswire/ -- GlySens Incorporated announced today that it has been awarded a two-year, two million dollar grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH).  The grant is intended to support human clinical evaluation of the GlySens second generation ICGM™ long term implantable glucose monitoring system.  Final preparations for launch of the trial are underway, and enrollment is expected to begin before the end of 2014.

"We are extremely pleased and grateful to have the support of NIDDK and the NIH as we take these next steps in the development of the GlySens ICGM system," said Joseph Lucisano, PhD, GlySens President and CEO.  "As appreciation continues to grow for the potential of continuous glucose monitoring to make a real difference in the lives of people with diabetes, the need to provide an effective, widely acceptable, patient-friendly product has never been greater.  We believe that our long term system approach, with its fully implantable sensor intended to operate continuously for one year without need for replacement, will provide the convenience and ease of use that patients desire and foster widespread application of continuous glucose monitoring in diabetes care.  The long-standing engagement of the NIH with our research program has provided tremendous value in helping us ensure that our approach aims to serve a broad range of patient needs while we also maintain the highest level of scientific rigor in our efforts.  As with our other previous NIH sponsored projects, including the completed human clinical evaluation of the first generation ICGM system, we look forward to conducting this upcoming clinical trial with NIH support."

About GlySens Incorporated
GlySens Incorporated is a privately held corporation devoted to developing the world's first truly long term continuous glucose monitoring system, intended to dramatically improve the lives of people with diabetes.  The GlySens fully implanted sensor—demonstrated up to 18-month lifetime in preclinical testing—wirelessly links to a convenient external receiver, designed to provide continuous, at-a-glance glucose measurement, recording, and alerts regarding hypo- and hyperglycemic glucose excursions.  In contrast with other approaches that may require calibration multiple-times-per-day, system calibration checks of the GlySens sensor are designed to be required only infrequently, freeing users from the need for burdensome care and maintenance.  For people living with diabetes, the GlySens implantable continuous glucose monitoring system (the GlySens ICGM™ system) is intended to provide a means for easy, unobtrusive, worry-free glucose monitoring, and empower users by providing the information they need, while freeing them to live life on their own terms.  Additional information is available at www.glysens.com.

ICGM is a trademark of GlySens Incorporated.

Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE.

Research reported in this release was supported by National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under grant number R44DK077254.  The content of this release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


'/>"/>
SOURCE GlySens Incorporated
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. West Health Investment Fund invests in GlySens and RxAnte
2. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
3. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
4. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
5. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
6. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
7. Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
8. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
9. Accuray Incorporateds CEO to Speak at Morgan Stanley Global Healthcare Conference
10. Proacta Incorporated Announces IND Allowance for PR610
11. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2020)... ... August 27, 2020 , ... Bleep LLC, maker of the ... apnea patient, is the company’s new spokesperson. , “In my line of work, a ... I found the Bleep DreamPort it was a Bleeping no brainer for me,” said ...
(Date:8/26/2020)... ... August 26, 2020 , ... AseptiScope, a privately funded San Diego, ... the Year by MedTech Outlook. , “AseptiScope is pleased to receive this ... clinicians who wear gloves on their hands, goggles on their eyes, covers on their ...
(Date:8/26/2020)... ... 26, 2020 , ... Crossroads Hospice & Palliative Care Chief ... to her name. , That’s thanks to her completion of two additional certifications ... Compliance Officer (CPCO.) , The CHC is designed to mitigate compliance-related risks. ...
Breaking Medicine Technology:
(Date:9/1/2020)... Fla. (PRWEB) , ... September 01, 2020 , ... ... Reconstructive Surgeon with specialty fellowship training in aesthetic surgery of the face, breast, ... MD – the only female-owned premier boutique plastic surgery and aesthetic practice in ...
(Date:8/31/2020)... ... August 31, 2020 , ... Want to get moving, break up ... Research Foundation (CPARF) is thrilled to launch its fourth annual STEPtember campaign in the ... challenge, STEPtember meets everyone wherever they are at this moment — encouraging people to ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... A Cure for Covid-19 “PTS” with Mediation ... on the planet are in a state of panic, experiencing deep anxiety, immense stress, and ... now, a solution is timely when most people on the planet are experiencing a great ...
(Date:8/28/2020)... ... 28, 2020 , ... Ernst & Young LLP (EY US) ... Of The Year® 2020 Florida Award finalist. Now in its 34th year, the ... growth and prosperity as they build and sustain successful businesses that transform our ...
(Date:8/28/2020)... ... August 28, 2020 , ... Ziegler, a specialty investment ... investment in Synchronous Health, a tech-enabled behavioral health and well-being solutions provider. ... empathy with artificial intelligence (AI) to increase access and quality of behavioral health ...
Breaking Medicine News(10 mins):